[
    [
        {
            "time": "",
            "orginal_text": "7.19亿，仁和拿下多家企业",
            "features": {
                "keywords": [
                    "仁和",
                    "企业收购",
                    "资金规模"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "7.19亿，仁和拿下多家企业",
            "scores": {
                "News_content": "7.19亿，仁和拿下多家企业",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "中银基金旗下部分产品二季报出炉，个别债基标的受监管处罚，刘潇大幅加仓云南白药、丽珠集团、大参林",
            "features": {
                "keywords": [
                    "中银基金",
                    "二季报",
                    "监管处罚",
                    "云南白药",
                    "丽珠集团",
                    "大参林"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "中银基金旗下部分产品二季报出炉，个别债基标的受监管处罚，刘潇大幅加仓云南白药、丽珠集团、大参林",
            "scores": {
                "News_content": "中银基金旗下部分产品二季报出炉，个别债基标的受监管处罚，刘潇大幅加仓云南白药、丽珠集团、大参林",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "电报|中银基金首家公布二季报中银医疗保健第一重仓云南白药",
            "features": {
                "keywords": [
                    "中银基金",
                    "二季报",
                    "中银医疗保健",
                    "云南白药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "电报|中银基金首家公布二季报中银医疗保健第一重仓云南白药",
            "scores": {
                "News_content": "电报|中银基金首家公布二季报中银医疗保健第一重仓云南白药",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "医药行业周报：《2021年国家医保药品目录调整工作方案》出炉 重点关注意创新药投资机会",
            "features": {
                "keywords": [
                    "医药行业",
                    "医保药品目录",
                    "创新药",
                    "政策调整"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "医药行业周报：《2021年国家医保药品目录调整工作方案》出炉 重点关注意创新药投资机会",
            "scores": {
                "News_content": "医药行业周报：《2021年国家医保药品目录调整工作方案》出炉 重点关注意创新药投资机会",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]